New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2013
20:23 EDTALXN, RHHBYAlexion's price may be more than Roche would be willing to pay, Reuters says
A Roche (RHHBY) bid for Alexion (ALXN) would mark an attempt by Roche to diversify beyond its core cancer competencies through acquisitions but Alexion's valuation may be more than Roche would be willing to pay, says Reuters. Reference Link
News For ALXN;RHHBY From The Last 14 Days
Check below for free stories on ALXN;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:44 EDTALXNAlexion valuation looking increasingly compelling, says Stifel
Subscribe for More Information
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
11:53 EDTALXNAlexion price target raised to $214 from $196 at Piper Jaffray
Subscribe for More Information
06:43 EDTALXNAlexion raises 2014 adjusted EPS view to $4.95-$5.05 from $4.75-$4.85
Subscribe for More Information
06:41 EDTALXNAlexion reports Q2 adjusted EPS $1.12, consensus $1.07
Subscribe for More Information
06:17 EDTALXNAlexion's hypophosphatasia candidate MAA accepted by European Medicines Agency
Subscribe for More Information
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
11:48 EDTALXNStocks with call strike movement; EXPE ALXN
Subscribe for More Information
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
10:01 EDTALXNPegasystems appoints Warner Chief Compliance Officer
Subscribe for More Information
08:01 EDTALXNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use